Helicos Biosciences, the Cambridge, MA-based developer of gene sequencing instruments, has been delisted from the NASDAQ stock market, after noting in a regulatory filing that it was unlikely to meet listing requirements “due to the state of its finances and near-term business prospects.” Last month, Helicos named Ivan Trifunovich as its new CEO, and expanded its patent litigation strategy, accusing not just Menlo Park, CA-based Pacific Biosciences, but also San Diego-based Illumina and Carlsbad, CA-based Life Technologies of infringing on its patents.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
